Ruxolitinib shows activity against Hodgkin lymphoma but not primary mediastinal large B-cell lymphoma

The upregulated expression of the JAK/STAT pathway promotes tumor growth in Hodgkin lymphoma (HL) and primary mediastinal large B-cell lymphoma (PMBCL). Based on the hypothesis that JAK2 is a therapeutic targe...

Source: BMC Cancer - November 10, 2019 Category: Cancer & Oncology Authors: Seok Jin Kim, Dok Hyun Yoon, Hye Jin Kang, Jung Yong Hong, Ho Sup Lee, Sung Yong Oh, Ho-Jin Shin, Jee Hyun Kong, Jun Ho Yi, Kana Sakamoto, Young Hyeh Ko, Jooryung Huh, Seung-Sook Lee, Kengo Takeuchi, Dong-Yeop Shin, Cheolwon Suh & hellip; Tags: Research article Source Type: research